Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 50 of 104 publications.

Khan S, Copley-Merriman K, Heyes A, Hawe E, Hartley L, Kallmes K. Qualitative and quantitative evidence synthesis strategies to support JCA and IRA submissions. Poster to be given at the ISPOR Europe 2024; November 17, 2024. Barcelona, Spain.

Copley-Merriman K, Miller-Wilson LA, Costello J, Schwinn J, Edwards Y. Evidence gap analysis of the burden of illness and treatment of myasthenia gravis. Poster presented at the ISPOR 2024; May 7, 2024. Atlanta, GA. [abstract] Value Health. 2024 Jun; 27(6 Supplement):S384-5. doi: 10.1016/j.jval.2024.03.1792

Gildea L, Copley-Merriman C, Arvin-Berod C, Vande Walle K, Verheesen P, Stoykov I. Evidence gap analysis of the burden of illness and treatment of bullous pemphigoid. Poster presented at the ISPOR Europe 2023; November 13, 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 supplement):S27. doi: 10.1016/j.jval.2023.09.141

D'Souza V, Copley-Merriman C. Analysis: first year of the new early access authorization in France. Poster presented at the ISPOR Europe 2022; November 6, 2022. [abstract] Value Health. 2022 Dec 1; 25(12):S342. doi: 10.1016/j.jval.2022.09.1691

Copley-Merriman C, D'Souza V, Arvin-Berod C, Phillips G, Verheesen P, Heyerick A, Stoykov I. Evidence gap analysis of the burden of illness and treatment of pemphigus vulgaris and foliaceus. Poster presented at the ISPOR Europe 2022; November 6, 2022. Vienna, Austria. [abstract] Value Health. 2022 Dec 1; 25(12):S41. doi: 10.1016/j.jval.2022.09.198

Fernandez M, Copley-Merriman C, Arvin-Berod C, Phillips G, Gelinas D, Weiss R, Hofman E, Tse A. Evidence gap analysis of the burden of illness and treatment of chronic inflammatory demyelinating polyneuropathy. Poster presented at the ISPOR Europe 2022; November 6, 2022. Vienna, Austria. [abstract] Value Health. 2022 Dec 1; 25(12):S34. doi: 10.1016/j.jval.2022.09.164

Mordin M, Parrish W, Masaquel C, Bisson B, Copley-Merriman K. Intra-articular hyaluronic acid for osteoarthritis of the knee in the United States: a systematic review of economic evaluations. Clin Med Insights Arthritis Musculoskelet Disord. 2021 Nov 19;14:1-13. doi: 10.1177/11795441211047284

Copley-Merriman C, Yang X, Juniper M, Amin S, Yoo HK, Sen SS. Natural history and disease burden of neurofibromatosis type 1 with plexiform neurofibromas: a systematic review. Adolesc Health Med Ther. 2021 May 19;12:55-66. doi: 10.2147/AHMT.S303456

Copley-Merriman C, Mordin M. Use of pragmatic clinical trials in reimbursement decisions. In: Girman, CJ, Ritchey, ME, editors. Pragmatic randomized clinical trials: using primary data collection and electronic health records. 1st ed. Waltham: MA. Academic Press; 2021. p.445-60.

Bektas M, Copley-Merriman C, Khan S, Sarda SP, Shammo JM. Paroxysmal nocturnal hemoglobinuria: patient journey and burden of disease. J Manag Care Spec Pharm. 2020 Dec;26(12-b Suppl):S8-S14. doi: 10.18553/jmcp.2020.26.12-b.s8

Bektas M, Copley-Merriman C, Khan S, Sarda SP, Shammo JM. Paroxysmal nocturnal hemoglobinuria: role of the complement system, pathogenesis, and pathophysiology. J Manag Care Spec Pharm. 2020 Dec;26(12-b Suppl):S3-8. doi: 10.18553/jmcp.2020.26.12-b.s3

Bektas M, Copley-Merriman C, Khan S, Sarda SP, Shammo JM. Paroxysmal nocturnal hemoglobinuria: current treatments and unmet needs. J Manag Care Spec Pharm. 2020 Dec;26(12-b Suppl):S14-20. doi: 10.18553/jmcp.2020.26.12-b.s14

Copley-Merriman C, Yang X, Juniper M, Amin S, Yoo HK, Sen S. Impact of neurofibromatosis type 1 and plexiform neurofibromas on patient-reported health-related quality of life. Poster presented at the 2020 ISPOR Virtual Conference; May 2020. [abstract] Value Health. 2020 May 1; 23(Suppl 1):S344. doi: 10.1016/j.jval.2020.04.371

Khan S, Mordin M, Barrows SB, Copley-Merriman K. Similarities & differences in Global Value Dossier (GVD) and Academy of Managed Care Pharmacy (AMCP) dossier development. Poster presented at the 2019 ISPOR 24th Annual International Meeting; May 22, 2019. New Orleans, LA.

Barrows SM, Wright K, Copley-Merriman C, Kaye JA, Chioda M, Wiltshire R, Torgersen KM, Masters ET. Systematic review of sequencing of ALK inhibitors in ALK-positive non-small-cell lung cancer. Lung Cancer. 2019 Feb 8;2019:11-20. doi: 10.2147/LCTT.S179349

Masaquel C, Rothwell B, Bhaila R, Copley-Merriman C, Wolowacz S, Aguiar-Ibanez R, Patel N, Liu FX. A systematic review of utility estimates in melanoma in the adjuvant setting. Poster presented at the 2018 ISPOR 21st Annual European Congress; November 13, 2018. Barcelona, Spain.

Heyes A, McBride D, Pearson I, Copley-Merriman C. HTA and reimbursement considerations for rare diseases in European markets: what are the implications for manufacturers? Poster presented at the 2018 ISPOR 21st Annual European Congress; November 12, 2018. Barcelona, Spain.

Copley-Merriman C, Stevinson K, Liu FX, Wang J, Mauskopf J, Zimovetz EA, Chmielowski B. Direct costs associated with adverse events of systemic therapies for advanced melanoma: Systematic literature review. Medicine. 2018 Aug;97(31):e11736. doi: 10.1097/MD.0000000000011736

Barrows SM, Cai B, Copley-Merriman C, Wright KR, Castro CV, Soufi-Mahjoubi R. Systematic literature review of the antitumor effect of octreotide in neuroendocrine tumors. World J Meta-Anal. 2018 Jun 28;6(2):9-20.

Mordin M, Fernandez M, Pearson I, Copley-Merriman K, McBride D. Similarities and differences in European HTA evidence requirements: one for all or one for none? Presented at the 2018 ISPOR 23rd Annual International Meeting; May 22, 2018. Baltimore, MD.

Copley-Merriman K. Rare diseases: addressing the challenges in diagnosis, drug approval, and patient access - editorial. Value Health. 2018 May;21(5):491-2. doi: 10.1016/j.jval.2018.03.009

Barrows SM, Wright K, Copley-Merriman C, Kaye JA, Chioda M, Wiltshire R, Torgersen KM, Masters ET. Systematic Literature Review (SLR) of sequencing of Anaplastic Lymphoma Kinase (ALK) inhibitors in ALK-Positive Non-Small Cell Lung Cancer (NSCLC). Poster presented at the 2018 ISPOR 23rd Annual International Meeting; May 22, 2018. Baltimore, MD. [abstract] Value Health. 2018 May; 21(Suppl 1):S49-50. doi: 10.1016/j.jval.2018.04.291

Fernandez MM, Khan S, Mordin M, Copley-Merriman C, McBride D. Comparing literature review requirements for reimbursement submissions across the globe. Poster presented at the 2018 ISPOR 23rd Annual International Meeting; May 22, 2018. Baltimore, MD. [abstract] Value Health. 2018 May; 21(Suppl 1):S108. doi: 10.1016/j.jval.2018.04.732

Masaquel C, Hurley D, Barnett B, Krieger T, Pearson I, Copley-Merriman C, Kaye JA, Moy B. Clinical and economic burden of HER2-positive breast cancer recurrence in the US: a literature review. Poster presented at the 2017 San Antonio Breast Cancer Symposium; December 7, 2017. San Antonio, TX.

Barrows SM, Cai B, Wright K, Castro CV, Kaye JA, Copley-Merriman C, Soufi-Mahjoubi R. Systematic literature review of octreotide's antitumor effects in neuroendocrine tumors. Poster presented at the 2017 North American Neuroendocrine Tumor Society Annual Symposium; October 19, 2017. Philadelphia, PA.

Colosia AD, Yang J, Hillson E, Mauskopf J, Copley-Merriman C, Shinde V, Stoddard J. The epidemiology of medically attended respiratory syncytial virus in older adults in the United States: a systematic review. PLoS One. 2017 Aug 10;12(8):e0182321. doi: 10.1371/journal.pone.0182321

Winnette R, Hess LM, Nicol SJ, Tai DF, Copley-Merriman C. The patient experience with soft tissue sarcoma: a systematic review of the literature. Patient. 2017 Apr;10(2):153-62. doi: 10.1007/s40271-016-0200-1

Copley-Merriman C, Zelt S, Clark M, Gnanasakthy A. Impact of measuring patient-reported outcomes in dermatology drug development. Patient. 2017 Apr;10(2):203-13. doi: 10.1007/s40271-016-0196-6

Copley-Merriman K. Value for money: assessing the value of a pharmaceutical product. Presented at the University of Michigan Translational Pharmacology Course 621; October 6, 2016.

Masaquel C, Jerusalem G, Copley-Merriman K, Ray D, Higuchi K, Caceres V. Economic burden of advanced breast cancer. Poster presented at the 2016 ISPOR 21st Annual International Meeting; May 24, 2016. Washington, DC. [abstract] Value Health. 2016 May; 19(3):A146.

Hess LM, Winnette R, Nicol S, Tai DF, Copley-Merriman K. Understanding the patient experience with soft tissue sarcoma: a systematic review of the literature. Poster presented at the 2016 American Society of Clincial Oncology Quality Care Symposium; February 26, 2016. Phoenix, AZ.

Khan S, Zimovetz E, Healey P, Copley-Merriman K. Biologics in ulcerative colitis (UC): treatment guidelines, health technology assessments (HTA). Poster presented at the 2015 ISPOR 18th Annual European Congress; November 2015. Milan, Italy. [abstract] Value Health. 2015 Nov; 18(7):A633.

Copley-Merriman K. Value for money: health economics. Presented at the University of Michigan; October 29, 2015. Ann Arbor, MI.

Copley-Merriman C, Zelt S, Clark M, Gnanasakthy A. Benefits of patient-reported outcomes in dermatology drug development. Poster presented at the 2015 ISPOR 20th Annual International Meeting; May 2015. Philadelphia, PA.

Zhou X, Wang J, Zhang J, Copley-Merriman C, Torigoe Y, Reyes C, Seymour JF, Offner FC, Trneny M, Salles GA. Symptoms and toxicity of rituximab maintenance relative to observation following immunochemotherapy in patients with follicular lymphoma. Hematology. 2015 Apr;129(36). doi: 10.1179/1607845414Y.0000000179

Brennan VK, Mauskopf JA, Colosia AD, Copley-Merriman K, Hass B, Palencia R. Utility estimates for patients with type 2 diabetes mellitus after experiencing a myocardial infarction or stroke: a systematic review. Expert Rev Pharmacoecon Outcomes Res. 2015 Feb;15(1):111-23.

Mordin M, Masaquel C, Abbott C, Copley-Merriman C. Factors affecting the health-related quality of life of patients with cervical dystonia and impact of treatment with abobotulinumtoxinA (Dysport): results from a randomised, double-blind, placebo-controlled study. BMJ Open. 2014 Oct 16;4(10):e005150. doi: 10.1136/bmjopen-2014-005150

Clark MJ, Harris N, Griebsch I, Kaschinski D, Copley-Merriman C. Patient-reported outcome labeling claims and measurement approach for metastatic castration-resistant prostate cancer treatments in the United States and European Union. Health Qual Life Outcomes. 2014 Jul 4;12(1):104.

Brennan VK, Colosia AD, Copley-Merriman K, Mauskopf J, Haas B, Psalencia R. Incremental costs associated with myocardial infarction and stroke in patients with type 2 diabetes mellitus: an overview for economic modeling. J Med Econ. 2014 Jul;17(7):469-80. doi: 10.3111/13696998.2014.915847

Copley-Merriman C, Zelt S, Stone G, Barrows SM, Mordin MM, Hogue SL. Emerging-market payer needs: how should these countries be included in dermatology drug development plans? Poster presented at the 2014 ISPOR 19th Annual International Meeting; June 4, 2014.

Rycroft C, Fernandez M, Copley-Merriman K. Systematic literature reviews at the heart of health technology assessment: a comparison across markets. Poster presented at the 2013 ISPOR 16th Annual European Congress; November 2013. [abstract] Value Health. 2013 Nov; 16(7):A481.

Harrison CN, Mesa RA, Kiladjian J-J, Al-Ali H-K, Gisslinger H, Knoops L, Squier M, Sirulnik A, Mendelson E, Zhou X, Copley-Merriman C, Hunter DS, Levy RS, Cervantes F, Passamonti F, Barbui T, Barosi G, Vannucchi AM. Health-related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy. Br J Haematol. 2013 Jul;162(2):229-39. doi: 10.1111/bjh.12375

Copley-Merriman K, Olanrewaju B, Hogue S. The temporal relationship between NSAIDS and risk of gastrointestinal, cardiovascular, and renal events: a systematic review. Poster presented at the 2013 ISPOR 18th Annual International Meeting; May 2, 2013. [abstract] Value Health. 2013 May; 16(3):A110.

Copley-Merriman C, Olanrewaju B, Hogue S. Systematic literature review of the temporal relationship between nsaid use and gastrointestinal, cardiovascular, or renal events. Poster presented at the 2013 ISPOR 18th Annual International Meeting; May 2013. New Orleans, LA. [abstract] Value Health. 2013 May; 16(3):A110.

Brennan VK, Colosia AD, Copley-Merriman C, Hass B, Palencia R. Systematic literature review of utilities relating to patients with type-2 diabetes mellitus experiencing a stroke or myocardial infarction. Poster presented at the 2013 ISPOR 18th Annual International Meeting; May 2013. New Orleans, LA. [abstract] Value Health. 2013 May; 16(3):A168. doi: 10.1016/j.jval.2013.03.841

Brennan VK, Colosia AD, Copley-Merriman C, Hass B, Palencia R. Systematic literature review of costs related to patients with type 2 diabetes mellitus experiencing a stroke or myocardial infarction. Poster presented at the 2013 ISPOR 18th Annual International Meeting; May 7, 2013. New Orleans, LA. [abstract] Value Health. 2013 May; 16(3):A162. doi: 10.1016/j.jval.2013.03.811

Mordin M, Copley-Merriman C, Mauskopf J, Sweeney C, Bhattacharyya S, Farup C, Beach W, Higgins L, McIntyre L. Surgical innovation: do we need a more balanced framework for evidence? Poster presented at the 2013 ISPOR 18th Annual International Meeting; May 3, 2013. [abstract] Value Health. 2013 May; 16(3):A247.

McIntyre LF, Beach WR, Higgins LD, Mordin MM, Mauskopf J, Sweeney CT, Copley-Merriman C. Evidence-based medicine, appropriate-use criteria, and sports medicine: how best to develop meaningful treatment guidelines. Arthroscopy. 2013 Mar 18;29(7):1224-9.

Xu J, Evans J, Coon C, Copley-Merriman K, Su Y. Measuring patient-reported outcomes in advanced gastric cancer. Ecancermedicalscience. 2013;7:351. doi: 10.3332/ecancer.2013.351.

Spinner DS, Birt J, Walter JW, Bowman L, Mauskopf J, Drummond MF, Copley-Merriman C. Do different clinical evidence bases lead to discordant health-technology assessment decisions? An in-depth case series across three jurisdictions. Clinicoecon Outcomes Res. 2013 Jan 1;5:69-85.